US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
KR100458403B1
(ko)
*
|
1997-09-29 |
2004-11-26 |
포인트 써러퓨틱스, 인크. |
생체외 조혈세포의 자극방법
|
US6803357B1
(en)
|
1998-02-02 |
2004-10-12 |
New England Medical Center Hospitals, Inc. |
Method of regulating glucose metabolism, and reagents related thereto
|
KR20010079669A
(ko)
*
|
1998-08-21 |
2001-08-22 |
바바라 피. 월너 |
기질 활성의 조절
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
CO5150173A1
(es)
*
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6110949A
(en)
*
|
1999-06-24 |
2000-08-29 |
Novartis Ag |
N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
ATE385421T1
(de)
*
|
2000-01-21 |
2008-02-15 |
Novartis Pharma Gmbh |
Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
|
JP2003520849A
(ja)
*
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
酵素dpp−ivの阻害剤であるn−置換2−シアノピロールおよび−ピロリン
|
WO2001062266A2
(en)
*
|
2000-02-25 |
2001-08-30 |
Novo Nordisk A/S |
Use of dpp-iv inhibitors for the treatment of diabetes
|
EP1263458B1
(en)
*
|
2000-03-08 |
2005-11-16 |
Novo Nordisk A/S |
Lowering serum cholesterol
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
JP2003528135A
(ja)
†
|
2000-03-31 |
2003-09-24 |
プロバイオドラッグ アーゲー |
糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
|
WO2002002560A2
(en)
|
2000-07-04 |
2002-01-10 |
Novo Nordisk A/S |
Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
WO2002022151A2
(en)
|
2000-09-18 |
2002-03-21 |
Osteometer Bio Tech A/S |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
EP1891948A1
(en)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Treatment of neurological and neuropsychological disorders
|
EP1328271B1
(en)
*
|
2000-10-27 |
2008-06-25 |
Probiodrug AG |
Treatment of neurological and neuropsychological disorders
|
WO2002067918A1
(fr)
*
|
2001-02-27 |
2002-09-06 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de diallylmethylamine
|
WO2002083066A2
(en)
|
2001-04-11 |
2002-10-24 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
DE60221983T2
(de)
|
2001-06-27 |
2008-05-15 |
Smithkline Beecham Corp. |
Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
|
JP4300108B2
(ja)
|
2001-06-27 |
2009-07-22 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
|
DE60222667T2
(de)
|
2001-06-27 |
2008-07-17 |
Smithkline Beecham Corp. |
Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
|
US8377877B2
(en)
|
2001-07-06 |
2013-02-19 |
Kemin Foods, L.C. |
Composition and method for reducing post-prandial blood glucose
|
DE60228972D1
(de)
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
US7459432B2
(en)
*
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
RU2353625C2
(ru)
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
EP1443919A4
(en)
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
|
CA2466870A1
(en)
*
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Methods for treating autoimmune disorders, and reagents related thereto
|
EP1469873A4
(en)
*
|
2001-11-26 |
2007-10-03 |
Tufts College |
PEPTIDOMIMETIC INHIBITORS OF POST-PROLINE CLEAVAGE ENZYMES
|
AU2002366452A1
(en)
*
|
2001-12-17 |
2003-06-30 |
Koninklijke Philips Electronics N.V. |
Magnetic resonance method
|
AU2002351752A1
(en)
|
2001-12-29 |
2003-07-30 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
WO2003068757A1
(en)
|
2002-02-13 |
2003-08-21 |
F. Hoffmann-La Roche Ag |
Novel pyridin- and pyrimidin-derivatives
|
JP4216197B2
(ja)
|
2002-02-13 |
2009-01-28 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規ピリジン及びキノリン誘導体
|
EP1499336A4
(en)
|
2002-04-30 |
2005-06-01 |
Tufts College |
PROTEASE INHIBITORS
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
NZ536832A
(en)
*
|
2002-06-03 |
2006-11-30 |
Novartis Ag |
The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
2型糖尿病治療剤
|
EP1578434A2
(en)
*
|
2002-07-09 |
2005-09-28 |
Point Therapeutics, Inc. |
Methods and compositions relating to isoleucine boroproline compounds
|
PT1528931E
(pt)
*
|
2002-08-09 |
2008-08-13 |
Prosidion Ltd |
Inibidores da dipeptidilpeptidase iv para a diminuição da taxa de aumento de peso crónico
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
JP4719465B2
(ja)
*
|
2002-09-04 |
2011-07-06 |
ディーエスエム アイピー アセッツ ビー.ブイ. |
インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
|
AU2002334520A1
(en)
|
2002-09-06 |
2004-03-29 |
Telefonaktiebolaget L M Ericsson (Publ) |
Composite power amplifier
|
EP1537880A4
(en)
|
2002-09-11 |
2009-07-01 |
Takeda Pharmaceutical |
PREPARATION FOR PROLONGED RELEASE
|
EP1539959A2
(en)
*
|
2002-09-18 |
2005-06-15 |
Centre Hospitalier de l'Université de Montréal (CHUM) |
Ghrh analogues
|
ATE469645T1
(de)
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
CA2518465A1
(en)
|
2003-03-25 |
2004-10-14 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7160449B2
(en)
|
2003-04-28 |
2007-01-09 |
Vanderbilt University |
Proline chiral columns with broad chiral selectivity
|
DE202004021723U1
(de)
|
2003-05-05 |
2010-07-15 |
Probiodrug Ag |
Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
JP5690463B2
(ja)
|
2003-05-05 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
AU2004251829B2
(en)
|
2003-06-20 |
2009-12-17 |
F. Hoffmann-La Roche Ag |
Hexahydropyridoisoqinolines as DPP-IV inhibitors
|
EP1638970B1
(en)
|
2003-06-20 |
2010-11-24 |
F. Hoffmann-La Roche AG |
Pyrid (2, 1-a) - isoquinoline derivatives as dpp-iv inhibitors
|
JP2007520441A
(ja)
*
|
2003-07-25 |
2007-07-26 |
コンジュシェム,インコーポレイティド |
持続性インスリン誘導体及びその方法
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1867560A
(zh)
|
2003-08-13 |
2006-11-22 |
武田药品工株式会社 |
4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
CN102302781A
(zh)
|
2003-10-15 |
2012-01-04 |
前体生物药物股份公司 |
谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
|
EP1680120A2
(en)
|
2003-11-03 |
2006-07-19 |
Probiodrug AG |
Combinations useful for the treatment of neuronal disorders
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7674913B2
(en)
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
CN1905876B
(zh)
|
2003-11-17 |
2010-06-09 |
诺瓦提斯公司 |
二肽基肽酶iv抑制剂的用途
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP2165703A3
(en)
|
2004-01-20 |
2012-03-28 |
Novartis Pharma AG |
Direct compression formulation and process
|
JP4996926B2
(ja)
|
2004-02-05 |
2012-08-08 |
プロビオドルグ エージー |
グルタミニルシクラーゼの新規の阻害剤
|
RU2379315C2
(ru)
*
|
2004-02-23 |
2010-01-20 |
Трастиз Оф Тафтс Колледж |
Ингибиторы дипептидилпептидазы iv
|
AU2011203039B2
(en)
*
|
2004-02-23 |
2013-02-21 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
UA85871C2
(uk)
|
2004-03-15 |
2009-03-10 |
Такеда Фармасьютікал Компані Лімітед |
Інгібітори дипептидилпептидази
|
WO2005118555A1
(en)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
BRPI0418906A
(pt)
*
|
2004-06-15 |
2007-11-27 |
Univ Vanderbilt |
colunas quirais novas com ampla seletividade quiral
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
WO2006017292A1
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
CA2574418A1
(en)
*
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Peptidase inhibitors
|
WO2006034435A2
(en)
*
|
2004-09-21 |
2006-03-30 |
Point Therapeutics, Inc. |
Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US20060263453A1
(en)
*
|
2004-11-01 |
2006-11-23 |
Thomas Smith |
Methods and compositions for modulating glutamate dehydrogenase
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
CA2590957A1
(en)
|
2004-12-20 |
2006-06-29 |
Markus Boehringer |
4-aminopiperidine derivatives
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
US7872124B2
(en)
|
2004-12-21 |
2011-01-18 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
JP2006232754A
(ja)
*
|
2005-02-25 |
2006-09-07 |
Gi Biopolis:Kk |
消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
CA2599419A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Alantos Pharmaceuticals Holding, Inc. |
Dipeptidyl peptidase-iv inhibitors
|
BRPI0610091B1
(pt)
*
|
2005-05-04 |
2021-08-03 |
Zealand Pharma A/S |
Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
NZ566799A
(en)
|
2005-09-14 |
2011-04-29 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
WO2007035629A2
(en)
|
2005-09-16 |
2007-03-29 |
Takeda Pharmaceutical Company Limited |
Process for the preparation of pyrimidinedione derivatives
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1971614A1
(en)
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
|
CN101365432B
(zh)
*
|
2005-12-16 |
2011-06-22 |
默沙东公司 |
二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
|
EP1973548A4
(en)
*
|
2005-12-19 |
2010-02-24 |
Tufts College |
LIGHT PROTEASES INHIBITORS AND THEIR LIGHT PROFORMS
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
GB0603252D0
(en)
*
|
2006-02-17 |
2006-03-29 |
Axcess Ltd |
Dissolution aids for oral peptide delivery
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EP1971862B1
(en)
|
2006-04-11 |
2010-11-10 |
Arena Pharmaceuticals, Inc. |
Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
|
JP2009533393A
(ja)
|
2006-04-12 |
2009-09-17 |
プロビオドルグ エージー |
酵素阻害薬
|
CA2810522A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Polymorphs
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US8748419B2
(en)
*
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
CN101472571B
(zh)
*
|
2006-06-16 |
2012-11-14 |
泰拉科斯有限公司 |
毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
WO2008022015A2
(en)
*
|
2006-08-11 |
2008-02-21 |
Trustees Of Tufts College |
Retro-inverso incretin analogues, and methods of use thereof
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2089389A2
(en)
|
2006-11-01 |
2009-08-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
EP2099767A1
(en)
|
2006-11-01 |
2009-09-16 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
|
US8642727B2
(en)
|
2006-11-08 |
2014-02-04 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
|
ITMI20062254A1
(it)
*
|
2006-11-24 |
2008-05-25 |
Acraf |
Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP5523107B2
(ja)
|
2006-11-30 |
2014-06-18 |
プロビオドルグ エージー |
グルタミニルシクラーゼの新規阻害剤
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
KR20090101362A
(ko)
|
2006-12-26 |
2009-09-25 |
파마시클릭스, 인코포레이티드 |
병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
|
WO2008112941A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Board Of Regents The University Of Texas System |
Composition and method for the treatment of diseases affected by a peptide receptor
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
WO2008116054A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Trustees Of Tufts College |
Inhibitors of fibroblast activation protein, and methods of use thereof
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
ES2533484T3
(es)
|
2007-04-18 |
2015-04-10 |
Probiodrug Ag |
Derivados de tiourea como inhibidores de la glutaminil ciclasa
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
JP5546451B2
(ja)
|
2007-06-04 |
2014-07-09 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
|
KR101536786B1
(ko)
|
2007-07-19 |
2015-07-14 |
다케다 야쿠힌 고교 가부시키가이샤 |
알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
|
ES2408384T3
(es)
|
2007-07-27 |
2013-06-20 |
Bristol-Myers Squibb Company |
Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
AU2008303922A1
(en)
*
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
EP2203448B1
(de)
*
|
2007-09-21 |
2011-06-22 |
Sanofi-Aventis |
Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
MY149648A
(en)
*
|
2007-09-21 |
2013-09-30 |
Sanofi Aventis |
Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
|
WO2009042922A2
(en)
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
WO2009058944A2
(en)
|
2007-11-01 |
2009-05-07 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009158380A1
(en)
|
2008-06-24 |
2009-12-30 |
Bristol-Myers Squibb Company |
Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
ES2614427T3
(es)
|
2008-11-07 |
2017-05-31 |
The General Hospital Corporation |
Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
|
JP2012509891A
(ja)
*
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ,インク. |
肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
|
CA2744697C
(en)
*
|
2008-11-26 |
2016-06-21 |
Satiogen Pharmaceuticals, Inc. |
Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
|
DE102008062136B4
(de)
|
2008-12-16 |
2012-05-03 |
Kamamed Ug |
Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
|
PL2395983T3
(pl)
|
2009-02-13 |
2020-09-07 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
EA022007B1
(ru)
|
2009-09-11 |
2015-10-30 |
Пробиодруг Аг |
Гетероциклические производные в качестве ингибиторов глутаминилциклазы
|
BR112012011733A2
(pt)
|
2009-11-13 |
2019-09-24 |
Bristol-Myers Squibb Company |
formulações de comprimido de liberação imediata
|
CN102711739B
(zh)
|
2009-11-13 |
2015-12-16 |
阿斯利康(瑞典)有限公司 |
双层片剂
|
EP2498757A1
(en)
|
2009-11-13 |
2012-09-19 |
Bristol-Myers Squibb Company |
Reduced mass metformin formulations
|
KR102668834B1
(ko)
|
2009-11-27 |
2024-05-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
KR101790806B1
(ko)
|
2010-03-10 |
2017-11-20 |
프로비오드룩 아게 |
글루타미닐 사이클라제(qc, ec 2.3.2.5)의 헤테로사이클릭 억제제
|
EP2556056A1
(en)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
ES2559209T3
(es)
|
2010-04-14 |
2016-02-11 |
Bristol-Myers Squibb Company |
Nuevos activadores de la glucocinasa y métodos de uso de los mismos
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8440655B2
(en)
|
2010-06-21 |
2013-05-14 |
Theracos, Inc. |
Combination therapy for the treatment of diabetes
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
NZ603319A
(en)
|
2010-06-24 |
2015-04-24 |
Boehringer Ingelheim Int |
Diabetes therapy
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
WO2012031124A2
(en)
|
2010-09-03 |
2012-03-08 |
Bristol-Myers Squibb Company |
Drug formulations using water soluble antioxidants
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101871011B1
(ko)
|
2010-09-22 |
2018-06-25 |
아레나 파마슈티칼스, 인크. |
Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
US11974971B2
(en)
|
2011-01-07 |
2024-05-07 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
WO2012094636A2
(en)
|
2011-01-07 |
2012-07-12 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
RU2607480C2
(ru)
|
2011-02-01 |
2017-01-10 |
Бристол-Майерс Сквибб Компани |
Фармацевтические композиции, содержащие аминосоединение
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2729468A4
(en)
|
2011-07-05 |
2015-03-18 |
Merck Sharp & Dohme |
TRICYCLIC HETEROCYCLES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
US8962636B2
(en)
|
2011-07-15 |
2015-02-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
CA2846852C
(en)
|
2011-08-30 |
2021-01-12 |
Trustees Of Tufts College |
Fap-activated proteasome inhibitors for treating solid tumors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2771003B1
(en)
|
2011-10-28 |
2017-04-19 |
Lumena Pharmaceuticals LLC |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
ES2832773T3
(es)
|
2012-01-06 |
2021-06-11 |
Anji Pharma Us Llc |
Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
|
AU2013207329B2
(en)
|
2012-01-06 |
2017-10-26 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
IN2015DN03795A
(US07981874-20110719-C00313.png)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
JP6278971B2
(ja)
|
2012-11-20 |
2018-02-14 |
レクシコン ファーマシューティカルズ インコーポレイテッド |
ナトリウムグルコース共輸送体1の阻害剤
|
WO2014102715A1
(en)
|
2012-12-24 |
2014-07-03 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014184742A1
(en)
|
2013-05-13 |
2014-11-20 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
FR3017536B1
(fr)
*
|
2014-02-18 |
2017-05-26 |
Univ La Rochelle |
Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
EP3273981B1
(en)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of diabetes
|
WO2017075289A1
(en)
|
2015-10-27 |
2017-05-04 |
Cytozyme Animal Nutrition, Inc. |
Animal nutrition compositions and related methods
|
US10674746B2
(en)
|
2015-10-27 |
2020-06-09 |
Cytozyme Animal Nutrition, Inc. |
Animal nutrition compositions and related methods
|
MX2018011177A
(es)
*
|
2016-04-04 |
2018-11-21 |
Res Triangle Inst |
Agonistas de receptor de neuropéptido s (npsr).
|
MX2018015089A
(es)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinacion de linagliptina y metformina.
|
DK3551651T3
(da)
|
2016-12-09 |
2024-05-13 |
Zealand Pharma As |
Acylerede glp-1/glp-2-dobbeltagonister
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
CN110996951A
(zh)
|
2017-04-03 |
2020-04-10 |
科赫罗斯生物科学股份有限公司 |
治疗进行性核上性麻痹的PPARγ激动剂
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
JOP20210009A1
(ar)
|
2018-07-19 |
2021-01-12 |
Astrazeneca Ab |
طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
|
MX2021003545A
(es)
|
2018-09-26 |
2021-05-27 |
Lexicon Pharmaceuticals Inc |
Formas solidas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2 -metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5- trihidroxi-6-(metiltio)tetrahidro-2h-piran-2-il)bencil)fenil)buta namida y metodos para su sintesis.
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
KR20220151434A
(ko)
*
|
2021-05-06 |
2022-11-15 |
엘지디스플레이 주식회사 |
범프를 포함하는 표시장치
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|